Drug Profile
Research programme: peptides therapeutics - Shionogi/PharmaIN
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator PharmaIN; Shionogi
- Class Peptides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Unspecified in Japan
- 28 Feb 2022 No recent reports of development identified for research development in Unspecified in USA
- 10 Jan 2018 Shionogi and PharmaIN Corporation enter collaborative research agreement for peptide therapeutics